Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer.
Nat. Med. 20, 1340-1347 (2014)
Genetically engineered mouse models (GEMMs) have dramatically improved our understanding of tumor evolution and therapeutic resistance. However, sequential genetic manipulation of gene expression and targeting of the host is almost impossible using conventional Cre-loxP-based models. We have developed an inducible dual-recombinase system by combining flippase-FRT (Flp-FRT) and Cre-loxP recombination technologies to improve GEMMs of pancreatic cancer. This enables investigation of multistep carcinogenesis, genetic manipulation of tumor subpopulations (such as cancer stem cells), selective targeting of the tumor microenvironment and genetic validation of therapeutic targets in autochthonous tumors on a genome-wide scale. As a proof of concept, we performed tumor cell-autonomous and nonautonomous targeting, recapitulated hallmarks of human multistep carcinogenesis, validated genetic therapy by 3-phosphoinositide-dependent protein kinase inactivation as well as cancer cell depletion and show that mast cells in the tumor microenvironment, which had been thought to be key oncogenic players, are dispensable for tumor formation.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
28.054
4.705
127
146
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Sprache
englisch
Veröffentlichungsjahr
2014
HGF-Berichtsjahr
2014
ISSN (print) / ISBN
1078-8956
e-ISSN
1546-170X
Zeitschrift
Nature medicine
Quellenangaben
Band: 20,
Heft: 11,
Seiten: 1340-1347
Verlag
Nature Publishing Group
Verlagsort
New York, NY
Begutachtungsstatus
Peer reviewed
Institut(e)
CF Comparative Medicine (AVM)
POF Topic(s)
30202 - Environmental Health
Forschungsfeld(er)
Genetics and Epidemiology
PSP-Element(e)
G-500900-001
PubMed ID
25326799
DOI
10.1038/nm.3646
WOS ID
WOS:000344724300025
Scopus ID
84964314145
Erfassungsdatum
2014-10-20